Clinical trials: Impulsivity
Addiction, Addiction, Alcohol
The Efficacy of a Mobile Application in Reducing Craving and Lapse Risk in Alcohol and Stimulants Problematic Use
The aim of the study is to evaluate the effectiveness of long-term and short-term app-based self-guided psychological interventions to reduce craving and lapse risk in users with substance use disorder or problematic substance…
- Conditions
- Addiction, Addiction, Alcohol, Addiction, Substance
- Trial name
- NCT05434416
- Testing
- mobile app
- Where
- Poland
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- PredictWatch
Opioid Use Disorder
Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL
This study will evaluate the efficacy, safety, and tolerability of oral naltrexone used in conjunction with buprenorphine in adults with Opioid Use Disorder transitioning from buprenorphine maintenance prior to the first dose of…
- Trial name
- NCT02696434
- Testing
- Naltrexone, Buprenorphine
- Where
- 9 sites in United States
- Volunteers
- 101 people
- Sponsor
- Alkermes, Inc.
Substance Dependence
An Open Label Positron Emission Tomography (PET) Study of GSK618334 in Healthy Male Subjects Using 11C-PHNO as PET Ligand
The purpose of this study is to investigate the relationship between the plasma concentrations of the study drug and the amount of the study drug bound to the D3 receptors of the brain after dosing of a new compound GSK618334.
- Trial name
- NCT00814957
- Testing
- GSK618334
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Opioid Abuse and Addiction
Nalmefene Implant in Healthy Subjects
The goal of this clinical trial is to learn how safe either one or two nalmefene implants are after remaining implanted for 4 or 12 weeks.
- Trial name
- NCT07325279
- Testing
- 1 Nalmefene implant, 2 Nalmefene implants
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- ReacX Pharmaceuticals, Inc.
ADHD - Combined Type, ADHD
Ocular-vestibular Biomarker Identification for ADHD
This study intends to establish a relationship between oculovestibular eye tracking measures, measures of ADHD, and medication prescribed for ADHD.
- Conditions
- ADHD - Combined Type, ADHD, ADHD Predominantly Inattentive Type, ADHD, Predominantly Hyperactive - Impulsive
- Trial name
- NCT04504890
- Testing
- EYE-SYNC
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Sync-Think, Inc.
Romano-Ward Syndrome, Long QT Syndrome
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients.
The objectives of the study are to investigate if KCNQ1 mutation in Romano-Ward long QT patients can be associated with changes in insulin regulation and with psychological features of compulsivity, impulsivity and behavioural…
- Conditions
- Romano-Ward Syndrome, Long QT Syndrome, Compulsive Behavior, Healthy Individuals
- Trial name
- PRIME (NCT04715256)
- Testing
- Cognitive assessment of obsessive-compulsive and impulsive behaviours, Genomic analysis, Glucoregulation assessment
- Where
- 2 sites in France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Biotrial
Nicotine Addiction, Drug Addiction
Clinical Trial of Smoking Cessation Mobile Phone Program
The Sponsor is doing a research study to assess the effects of a smartphone program designed to help users smoke less and eventually quit. When participants join, their involvement in the core study will last 8 weeks.
- Conditions
- Nicotine Addiction, Drug Addiction, Drug Dependence, Substance Use Disorder
- Trial name
- NCT02656745
- Testing
- Mobile Smoking Cessation Solution
- Where
- United States
- Volunteers
- 416 people
- Sponsor
- Click Therapeutics, Inc.
Attention Deficit Hyperactivity Disorder (ADHD)
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)
Children between the ages of 6-12 years who are diagnosed with impulsive aggression comorbid with ADHD and have participated in the 810P301 or 810P302 study were invited to participate in this study.
- Trial name
- NCT02691182
- Testing
- SPN-810
- Where
- United States
- Volunteers
- 491 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Cocaine Dependence
Vigabatrin for Treatment of Cocaine Dependence
The objective of this study is to demonstrate that a larger proportion of vigabatrin-treated subjects than placebo-treated subjects will be cocaine-free in the last 2 weeks of treatment.
- Trial name
- NCT00611130
- Testing
- vigabatrin
- Where
- 11 sites in United States
- Volunteers
- 186 people
- Sponsor
- Catalyst Pharmaceuticals, Inc.
Alcoholism
GSK1521498 Alcohol Interaction Study
The aim of the study is to assess the safety and tolerability of GSK1521498 in combination with alcohol and to determine the amount of GSK1521498 and alcohol in your blood after you have been given these together.
- Trial name
- NCT01366573
- Testing
- GSK1521498
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Opioid-use Disorder, Opioid-related Disorders
An Observational Study of Environmental and SocioEconomic Factors in Opioid Recovery
The RECOVER Study will examine clinical, environmental and socioeconomic factors in recovery from opioid use disorder (OUD) over a 24-month period following exit from a Phase III clinical program for a buprenorphine…
- Trial name
- RECOVER® (NCT03604861)
- Testing
- Not applicable - no defined intervention
- Where
- 35 sites in United States
- Volunteers
- 534 people
- Sponsor
- Indivior Inc.
Opiod Use Disorder
Safety, Tolerability, and Pharmacokinetics of Naltrexone Implant (DLP-160)
This is an Open-Label Study in Healthy Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of Switching from Oral Naltrexone HCL to DLP-160 (Naltrexone implant) to Intramuscular Vivitrol®
- Trial name
- NCT05304364
- Testing
- Combination Product: Naltrexone
- Where
- Australia
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Delpor, Inc.
Attention Deficit Hyperactivity Disorder (ADHD)
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of SPN-810 in the treatment of impulsive aggression in patients with Attention-Deficit/Hyperactivity Disorder (ADHD) in conjunction with standard…
- Trial name
- NCT02618434
- Testing
- SPN-810 (18 mg), SPN-810 (36 mg)
- Where
- 32 sites in United States
- Volunteers
- 297 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Opioid Dependence
An Open Label Study To Assess The Safety And Tolerability Of BEMA® Buprenorphine NX In Opioid Dependent Subjects
This is an open label study in opioid dependent subjects maintained on a stabilized dose of Suboxone tablets or films. The purpose is to assess the safety and tolerability of BEMA Buprenorphine NX administered once daily for 12…
- Trial name
- NCT01666119
- Testing
- BEMA Buprenorphine NX films
- Where
- 10 sites in United States
- Volunteers
- 249 people
- Sponsor
- BioDelivery Sciences International
Alcohol Dependence
ALK21-018: Effects of Medisorb® Naltrexone (VIVITROL®) on Alcohol Craving in Treatment-seeking, Alcohol-dependent Adults
This was a study of the effects of VIVITROL® on alcohol cue-induced craving and the associated brain activation patterns in alcohol-dependent adults who had recently completed alcohol detoxification and were seeking further…
- Trial name
- NCT00511836
- Testing
- VIVITROL 380 mg
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Alkermes, Inc.
Pain, Pain, Acute
Assessing Opioid Care Practices Using CPV Patient Simulation Modules
This study will test the quality of opioid-related physician care decisions using a patient-simulation based measurement and feedback approach that combines multiple-choice care decisions with real-time, personalized scoring and…
- Conditions
- Pain, Pain, Acute, Pain, Chronic, Pain, Neuropathic
- Trial name
- NCT04080037
- Testing
- Quality IQ Patient Simulations
- Where
- United States
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Qure Healthcare, LLC
Obsessive-Compulsive Behavior
rTMS Device for Improvement of Obsessive and Compulsive Behaviors
The goal of this investigational study is to evaluate if the treatment using EXOMIND(BTL-699-2) device is able to improve severity of obsessive and compulsive symptoms in adults (aged 22 and older).
- Trial name
- NCT07679750
- Testing
- EXOMIND (BTL-699-2) Active treatment
- Where
- 3 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- BTL Industries Ltd.
Patient Diagnosed With OCD and Resistant to SSRI Treatment, Failed SSRI Over 12 Weeks at Appropriate Doses
Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy
The purpose of this study is to determine whether AFQ056 as an add on therapy to SSRIs can have beneficial effects by reducing the total score of Y-BOCS (Yale and Brown Obsessive Compulsive Scale) in OCD patients resistant to…
- Trial name
- NCT01813019
- Testing
- AFQ056
- Where
- 15 sites in United States, Bulgaria and 3 more
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Opioid Dependence
The Safety of Using Buprenorphine With Naloxone in a Buccal Film to Initiate Treatment of Opioid Dependent Subjects
A randomized, double blind, active controlled study in approximately 40 opioid dependent subjects. Study duration is up to five days and includes a maximum of 3 days confinement in the clinic.
- Trial name
- NCT02516436
- Testing
- BEMA Buprenorphine NX, Buprenorphine
- Where
- 3 sites in United States
- Sponsor
- BioDelivery Sciences International
Opiate Addiction, Medication Non-adherence
Using Artificial Intelligence To Monitor Medication Adherence in Opioid Replacement Therapy
This study uses an artificial intelligence platform to automatically confirm medication ingestion. The Health Insurance Portability and Accountability Act (HIPAA)-compliant platform can be downloaded as an 'app' onto any…
- Conditions
- Opiate Addiction, Medication Non-adherence, Addiction, Opioid Dependence
- Trial name
- NCT02243670
- Testing
- AiCure monitoring and intervention
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- AiCure